Ricardo Estape, MD
Gynecologic Oncology · Miami, FLNPI 1427012772
Payments from drug & device makers
Across 553 payments — averaging $989.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Momentis Surgical Inc.$191K
- Conmed Corporation$132K
- Intuitive Surgical$90K
- GSK$46K
- Pfizer$45K
- Johnson & Johnson$18K
- plus $24K from 26 others
Across 1 payment — averaging $40,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- New Wave Endo-surgical Corp.$40K
What the payments were for
- Royalty or licence$11,3282%
- Consulting fees$316,34169%
- Speaking & faculty fees$12,0783%
- Travel & lodging$41,6429%
- Food & beverage$17,4384%
- Education$58,14213%
- Gifts$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Momentis Surgical Inc. | 107 | $190,532 |
| Conmed Corporation | 46 | $132,281 |
| Intuitive Surgical | 173 | $90,244 |
| GSK | 52 | $45,889 |
| Pfizer | 10 | $45,222 |
| Johnson & Johnson(2 entities) | 21 | $18,327 |
| Innovative Medical Products, Inc. | 5 | $11,328 |
| Activ Surgical, Inc. | 8 | $8,395 |
| Medical Device Business Services, Inc. | 11 | $1,075 |
| AstraZeneca | 17 | $490 |
| Hologic Sales And Service, LLC | 8 | $378 |
| Merck | 16 | $319 |
| AbbVie | 18 | $312 |
| Biom'up France SAS | 2 | $268 |
| Seagen Inc. | 10 | $240 |
| Tesaro, Inc. | 10 | $210 |
| Eisai Inc. | 10 | $210 |
| Baxter Healthcare | 3 | $188 |
| Sumitomo Pharma America, Inc. | 5 | $174 |
| Virtual Incision Corporation | 3 | $162 |
| Medtronic | 1 | $125 |
| Astellas Pharma US Inc | 5 | $115 |
| Coloplast | 1 | $86 |
| Innovation Technologies Inc | 1 | $85 |
| Coopersurgical, Inc. | 2 | $72 |
| On Target Laboratories, Inc | 1 | $61 |
| Agiliti Surgical, Inc. | 1 | $51 |
| Verity Pharmaceuticals Inc. | 2 | $36 |
| Myovant Sciences Inc. | 1 | $28 |
| Springworks Therapeutics, Inc. | 1 | $22 |
| Vertex | 1 | $20 |
| Smith+Nephew | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Anovo Surgical System$189,356
- AIRSEAL$130,670
- Da Vinci Surgical System$85,241
- VISTASEAL$13,330
- DA VINCI SP$1,000
- ActivSight$384
- Hominis Surgical System$284
- HemoBlast Bellows$268
- LigaSure$125
- MYFEMBREE$125
- Mira!$120
- TISSEEL$103
How this compares
$546,960 in reported general payments places this provider in the 85th percentile of 117 gynecologic oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 19 | $348,447 |
| MyrbetriqMirabegron | 22 | $10,738 |
| Ibuprofen | 350 | $1,369 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $994 |
| Estradiol | 13 | $800 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 162 | $588 |
| Clobetasol EmollientClobetasol Propionate/Emoll | 11 | $558 |
| Ondansetron OdtOndansetron | 30 | $430 |
| Prochlorperazine Maleate | 21 | $292 |
| Pantoprazole Sodium | 28 | $197 |
| Clobetasol Propionate | 11 | $151 |
| Oxybutynin Chloride ErOxybutynin Chloride | 20 | $113 |
| Gabapentin | 15 | $112 |
| Ciprofloxacin Hcl | 12 | $99 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $490 | $348,44719 claims |
| Astellas Pharma US IncMyrbetriq | $115 | $10,73822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 117 gynecologic oncology providers in Florida.
Other gynecologic oncology in Miami
- Matthew SchlumbrechtMiami$16.7M
- John DiazMiami$3.7M
- Jean-Marie StephanMiami$192K
- Troy GatcliffeMiami$172K
- Joseph PearsonMiami$59K
- Laurel KingMiami$38K
- Navya NairMiami$19K
- Eric SchroederMiami$10K
- Brian SlomovitzFort Lauderdale$13.9M
- Bradley MonkWest Palm Beach$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.